Tarsus Pharmaceuticals Inc.
TARS | NASDAQ
$77.46
-$0.63 (-0.81%)
At close: Sep 21, 2026, 4:00 PM ET
$77.46
$0 (0.00%)
After-hours:
Sep 21, 2026, 7:30 PM ET
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
Revenue | 451.36M | 182.95M | 17.45M | 25.82M | 57.03M | n/a |
Cost of Revenue | 30.68M | 12.83M | 1.59M | 955K | 2.08M | 246K |
Gross Profit | 420.68M | 170.13M | 15.85M | 24.86M | 54.95M | -246K |
Operating Income | -70.97M | -120.57M | -143.16M | -62.71M | -12.16M | -26.98M |
Interest Income | 15.75M | 15.01M | 10.34M | 3.5M | 36K | 188K |
Pretax Income | -64.36M | -115.55M | -135.89M | -62.1M | -13.77M | -26.81M |
Net Income | -66.42M | -115.55M | -135.89M | -62.09M | -13.83M | -26.81M |
Selling & General & Admin | 427.32M | 237.31M | 108.7M | 44.95M | 25.4M | 7.93M |
Research & Development | 64.32M | 53.39M | 50.31M | 42.62M | 41.71M | 18.83M |
Other Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 491.65M | 290.7M | 159.01M | 87.57M | 67.11M | 26.74M |
Interest Expense | 8.94M | 7.45M | 3.23M | 2.06M | n/a | 188K |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 522.33M | 303.52M | 160.61M | 88.53M | 69.18M | 26.98M |
Income Tax Expense | 2.06M | n/a | n/a | -4K | 55K | 1K |
Shares Outstanding (Basic) | 41.78M | 37.6M | 29.38M | 24.62M | 20.55M | 20.32M |
Shares Outstanding (Diluted) | 41.78M | 37.6M | 29.38M | 24.62M | 20.55M | 20.32M |
EPS (Basic) | -1.59 | -3.07 | -4.62 | -2.52 | -0.67 | -1.32 |
EPS (Diluted) | -1.59 | -3.07 | -4.62 | -2.52 | -0.67 | -1.32 |
EBITDA | -53.61M | -106.48M | -131.67M | -59.71M | -13.46M | -26.56M |
EBIT | -55.42M | -107.71M | -132.55M | -60.03M | -13.77M | -26.81M |
Depreciation & Amortization | 1.82M | 1.23M | 877K | 326K | 312K | 246K |
Add to Watchlist
Select watchlists to add or remove TARS